Monograph Details

Infections & Infestations > Bacterial infections
CIPRO XR
Manufacturer
Bayer Corp, Pharmaceutical Div.
Legal Classification
Rx
Pharmacological Class
Quinolone.
Generic Name
Ciprofloxacin (as HCl and betaine) 500mg, 1000mg; ext-rel tabs.
Also
CIPRO
CIPRO IV CONCENTRATE
CIPRO IV PREMIXED
CIPRO ORAL SUSPENSION
Indications
Susceptible infections including UTIs, acute uncomplicated pyelonephritis.
Children
<18yrs: not recommended.
Adults
Swallow whole. ≥18yrs: Uncomplicated UTIs: 500mg once daily for 3 days. Complicated UTIs, acute uncomplicated pyelonephritis: 1000mg once daily for 7–14 days; renal impairment (CrCl <30mL/min): 500mg once daily for 7–14 days. Coincide dose for end of dialysis.
Contraindications
Concomitant tizanidine.
Precautions
XR not interchangeable with other forms. Renal (except XR tabs for uncomplicated UTIs) or hepatic dysfunction: reduce dose. Increased risk of tendinitis or tendon rupture esp. in patients >60yrs, or those with kidney, heart or lung transplants. Discontinue if tendon pain, inflammation, or rupture occurs; if rash, phototoxicity, or other sign of hypersensitivity occurs; or if CNS disorders or neuropathy occurs. Conditions that increase seizure risk. History of prolonged QT interval. Hypokalemia. History of joint-related disorders (esp. children). Maintain adequate hydration, avoid alkaline urine to avoid crystalluria. Avoid excessive sun and UV light. May mask symptoms of syphilis; test for syphilis before treating gonorrhea, then follow-up after 3 months. Monitor blood, renal, hepatic function in prolonged use. Elderly. Pregnancy (Cat.C), nursing mothers: usually not recommended.
Interactions
Avoid theophylline (increases theophylline levels; may potentiate other CYP1A2 substrates), urinary alkalinizers; oral forms with antacids, calcium, iron, zinc, sucralfate, buffered forms of didanosine, other highly buffered drugs (may give ciprofloxacin 2 hrs before or 6 hrs after); high ciprofloxacin doses with NSAIDs (increases seizure risk). Potentiates caffeine. Potentiated by probenecid. Severe hypoglycemia with glyburide (rare). Increased serum creatinine with cyclosporine. Monitor methotrexate, oral anticoagulants (potentiation), phenytoin (variable effects). Increased risk of tendinitis and tendon rupture with corticosteroids. Caution with other drugs that lower seizure threshold. Increased risk of QT prolongation with Class IA or III antiarrhythmics. Reduced absorption with omeprazole (XR).
Adverse Reactions
GI upset, headache, CNS disturbances (eg, convulsions, dizziness, nervousness, insomnia, nightmares, paranoia), rash, eosinophilia, elevated liver enzymes, photosensitivity, Stevens-Johnson syndrome, myalgia, tendinitis/rupture, joint-related disorders (children), local reactions (inj); rare: increased intracranial pressure, toxic psychosis; peripheral neuropathy.
Extra Text
Note: See MMWR Vol 50, No.42 (Oct. 26, 2001) for more information on anthrax.
How Supplied
Tabs 250mg, 500mg—100
750mg—50
Oral Susp—100mL
Inj Conc (20mL, 40mL)—1
Infusion (100mL, 200mL)—1
XR Tabs—50, 100
Additional Resources
Related Prescribing Note